Autonomix Medical Granted U.S. Patent Titled 'Systems And Methods For Treating Cancer And/Or Augmenting Organ Function'

The patent expands the Company’s intellectual property protection for technologies designed to sense, map and selectively target nerves associated with tumors, cancer-related pain, organ function and other autonomic nervous system disorders.

The patent covers minimally invasive systems designed to sense and map electrophysiological activity in nerves associated with tumors or metastatic cells and use that information to guide targeted treatment. The technology includes catheter-based microsurgical tools designed to record neural signals and deliver energy or therapeutic agents to selectively block or modulate identified nerves.

The patent describes technologies intended to:

• Sense and map electrophysiological activity associated with tumors or metastatic cells;
• Use neural mapping information to identify and guide treatment of targeted nerves;
• Selectively block or modulate tumor-associated nerves to address cancer-related pain;
• Deliver therapeutic energy or agents through minimally invasive catheter-based systems;
• Target neural pathways that may influence tumors and the surrounding tumor microenvironment; and
• Modulate autonomic nervous system signaling associated with organ function.
  
  
  
   

The patent also describes potential applications across a range of solid tumors, including pancreatic, prostate, breast, colorectal, liver, ovarian and bone cancers.

The newly issued patent builds upon Autonomix's expanding intellectual property portfolio, which includes previously issued patents covering autonomic nervous system assessment, neural sensing, treatment guidance and transvascular neuromodulation technologies. Together, these patents support the Company's strategy of developing differentiated technologies designed to precisely identify and target disease-associated nerves across multiple therapeutic applications.

Autonomix continues to advance its proprietary technology platform designed to detect and differentiate neural signals with significantly greater sensitivity than conventional technologies, supporting the development of precision nerve-targeted therapies intended to improve patient outcomes while minimizing unintended effects on surrounding tissue.